sumatriptan - Profile

What are the generic sources for sumatriptan and what is the scope of patent protection?

Sumatriptan is the generic ingredient in ten branded drugs marketed by Glaxosmithkline, Cipla, Lannett Co Inc, Padagis Israel, Regcon Holdings, Tonix Meds, Meridian Medcl, Alembic, Antares Pharma Inc, Baxter Hlthcare Corp, Caplin, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hikma, Norvium Bioscience, Onesource Specialty, Ph Health, Sandoz, Sun Pharm, Teva Parenteral, Teva Pharms Usa, Wockhardt Bio Ag, Zydus, Endo Operations, Currax, Teva Branded Pharm, Aurobindo Pharma, Dr Reddys Labs Inc, Fosun Pharma, Hikma Pharms, Ipca Labs Ltd, Mylan, Orbion Pharms, Roxane, Sun Pharm Inds, Sun Pharm Inds Ltd, Teva, Vkt Pharma, Watson Labs, and Zhejiang, and is included in fifty-one NDAs. There are thirty-six patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Sumatriptan has one hundred and three patent family members in thirty-three countries.

There are six tentative approvals for this compound.

Summary for sumatriptan

International Patents:	103
US Patents:	36
Tradenames:	10
Applicants:	41
NDAs:	51

Generic filers with tentative approvals for SUMATRIPTAN

Applicant	Application No.	Strength	Dosage Form
		EQ 25MG BASE	TABLET;ORAL
		EQ 100MG BASE	TABLET;ORAL
		EQ 50MG BASE	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

US Patents and Regulatory Information for sumatriptan

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	IMITREX	sumatriptan	SPRAY;NASAL	020626-001	Aug 26, 1997	AB	RX	Yes	Yes
Glaxosmithkline	IMITREX	sumatriptan	SPRAY;NASAL	020626-002	Aug 26, 1997		DISCN	No	No
Glaxosmithkline	IMITREX	sumatriptan	SPRAY;NASAL	020626-003	Aug 26, 1997	AB	RX	Yes	Yes
Cipla	SUMATRIPTAN	sumatriptan	SPRAY;NASAL	214209-001	Feb 22, 2021	AB	RX	No	No
Lannett Co Inc	SUMATRIPTAN	sumatriptan	SPRAY;NASAL	204841-001	Feb 19, 2016	AB	RX	No	No
Lannett Co Inc	SUMATRIPTAN	sumatriptan	SPRAY;NASAL	204841-002	Feb 19, 2016	AB	RX	No	No

EU/EMA Drug Approvals for sumatriptan

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Galpharm Healthcare Ltd.	Sumatriptan Galpharm	sumatriptan	EMEA/H/C/002140	Refused	yes	no	no		2012-02-09

International Patents for sumatriptan

Country	Patent Number	Title	Estimated Expiration
European Patent Office	4483958
France	25C1007
Canada	3088989
United Kingdom	2600026
World Intellectual Property Organization (WIPO)	2015095389
Poland	3678649

Supplementary Protection Certificates for sumatriptan

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3678649	301317	Netherlands		PRODUCT NAME: COMBINATIE VAN EPINEFRINE OF EEN ZOUT DAARVAN, EN DODECYLMALTOSIDE; REGISTRATION NO/DATE: EU1/24/1846 20240823
3678649	122025000010	Germany		PRODUCT NAME: KOMBINATION AUS EPINEPHRIN AND DODECYLMALTOSID, IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/24/1846 20240822
3678649	LUC00378	Luxembourg		PRODUCT NAME: COMBINAISON D'EPINEPHRINE ET DE DODECYLMALTOSIDE, SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20250211
3678649	2025C/508	Belgium		PRODUCT NAME: COMBINATIE VAN EPINEPHRINE EN DODECYLMALTOSIDE, IN ALLE VORMEN BESCHERMD DOOR HET BASISOCTROOI; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20240823
3678649	CA 2025 00007	Denmark		PRODUCT NAME: KOMBINATION AF EPINEPHRIN ELLER ET SALT DERAF, OG DODECYLMATOSID; REG. NO/DATE: EU/1/24/1846 20240823
3678649	C20250011	Finland

Summary
This analysis evaluates the investment potential, market dynamics, and financial trajectory of sumatriptan, a leading medication for acute migraine management. The drug’s patent status, market size, competitive landscape, regulatory environment, and growth prospects are discussed comprehensively. Sumatriptan, marketed primarily by GlaxoSmithKline and other pharmaceutical companies, faces key challenges including patent expirations, generics competition, and evolving regulatory standards. Despite these challenges, the global migraine treatment market exhibits steady growth driven by increasing prevalence and advanced formulations. Investors should consider market saturation, lifecycle management strategies, and emerging alternatives in decision-making.

---

What is Sumatriptan and Its Current Market Status?

Attribute	Details
Therapeutic Class	Selective serotonin receptor agonist (triptan)
Market Launch Year	1991
Approved Indications	Acute migraine with or without aura, cluster headaches
Formulations Available	Oral tablets, nasal spray, subcutaneous injections
Major Manufacturers	GlaxoSmithKline, Teva, Mylan, Sun Pharmaceutical
Patent Status	Patents expired in multiple markets (e.g., US 2007)

Market Overview:
Sumatriptan remains a cornerstone in migraine therapy with an estimated global market valuation of USD 1.2 billion in 2022, projected to grow at a CAGR of 3.5% through 2030 [1]. The drug's extensive brand recognition and multiple formulations support steady revenue streams, although blockbuster status diminishes due to patent expiries and generics erosion.

---

Market Dynamics and Competitive Landscape

Last updated: February 3, 2026

1. Market Growth Drivers

• Increasing Migraine Prevalence: Over 1 billion individuals globally suffer from migraines, with rising incidence influenced by lifestyle changes and urbanization [2].
• Expanded Diagnosis and Awareness: Improved diagnostic methods and awareness campaigns boost treatment rates.
• Development of New Formulations: Nasal sprays and autoinjectors improve patient compliance and expand the market.
• Shift toward Fast-Acting Treatments: Innovations in delivery methods foster market growth.

2. Key Challenges

• Patent Expiry and Generics: US patent for sumatriptan expired in 2007, leading to intense price competition.
• Emergence of Newer Agents: Devices like ditans (e.g., lasmiditan) and CGRP antagonists (e.g., erenumab) provide alternatives, impacting market share.
• Regulatory and Price Pressures: Cost containment initiatives limit pricing power in several markets.

3. Competitive Landscape Table

Player	Product	Formulations	Market Share (2022)	Notes
GlaxoSmithKline	Imitrex (Sumatriptan)	Oral, nasal, injection	~45%	Dominant past patent expiration
Teva	Sumatriptan (Generic)	Oral, nasal, injection	---	Price leader post-patent
Promius Pharma	Sumatriptan Nasal Powder	Nasal	Small but growing	Focus on nasal delivery
Lilly / Novartis	Emgality (CGRP inhibitor)	Injectable	Competitive alternative	Market growth impacts triptan share

4. Regulatory Environment

• Key markets like US, EU, and Japan have stringent approval processes.
• Post-market surveillance focuses on cardiovascular safety.
• Fast-track approvals for new formulations.

---

Financial Trajectory and Investment Outlook

1. Revenue and Sales Trends (2010–2022)

Year	Estimated Global Sales (USD million)	Comments
2010	1,050	Patent maintained, market dominance
2015	1,150	Slight growth, market maturity
2020	1,250	Market saturation, minor growth
2022	1,200	Post patent expiries impact

Note: Revenue plateauing reflects patent expiries, intensified competition, and the gradual shift to newer classes of migraine therapies.

2. Revenue Breakdown by Formulation

Formulation	Market Share (2022)	Comments
Oral tablets	~60%	Largest segment, mature market
Nasal spray	~25%	Growing preference for rapid relief
Subcutaneous injections	~15%	Used in severe cases, less common

3. Lifecycle Management and Future Revenue Streams

• New Formulations: Auto-injectors, soluble tablets.
• Combination Therapy: Sumatriptan combined with NSAIDs.
• Regional Expansions: Countries like China and India show potential for increased penetration due to rising healthcare infrastructure.
• Market Entrants: Biosimilar development may further erode pricing and market share.

4. Investment Risks and Opportunities

Risks	Opportunities
Patent expiries and generics leading to price erosion	Lifecycle management strategies, new formulations
Competitive emergence of novel therapeutics	Market expansion in underserved regions
Regulatory and reimbursement pressures	Collaboration with biotech firms for innovation

---

Comparison with Emerging and Alternative Therapies

Therapy Type	Mechanism	Market Share (2022)	Advantages	Limitations
Triptans (Sumatriptan)	Serotonin receptor agonist	~45% (global)	Fast onset, well-understood safety profile	Cardiovascular risks, contraindications
CGRP Monoclonal Antibodies	Calcitonin gene-related peptide	~25%	Preventive, long-lasting, target-specific	Cost, initiation time
Ditans (Lasmiditan)	Serotonin 5-HT1F receptor agonist	Emerging	Fewer cardiovascular risks	Limited long-term data
Non-pharmacological therapies	Behavioral, lifestyle modifications	Growing	No adverse drug effects	Limited efficacy for severe cases

Market Outlook: Existing triptan therapies like sumatriptan will coexist with newer agents, with a likely decline in market share over the next decade as preventive therapies expand.

---

Implications for Investors

Key Considerations	Strategic Actions
Patent expirations have commoditized sumatriptan markets	Focus on lifecycle management, switch to high-margin formulations
Competitive offerings include CGRP inhibitors and ditans	Diversify portfolio to include emerging therapies
Regional market expansions show growth potential	Invest in emerging markets infrastructure and regulatory pathways
Price erosion due to generics and biosimilars	Emphasize branding, marketing, and new delivery systems
Regulatory environment favors innovation in formulations	Invest in R&D for novel sumatriptan derivatives or combo drugs

---

Key Takeaways

• Sumatriptan retains a significant role in the global migraine treatment market, with steady revenues but declining premium potential due to patent expiries.
• Market dynamics are influenced by increasing migraine prevalence, formulary innovations, and competition from biologics and novel agents.
• The future financial trajectory depends on effective lifecycle management, formulation innovation, and regional expansion.
• Investors should balance short-term revenue declines from generic competition with long-term gains from pipeline diversification and expanding regional markets.
• Emerging therapies such as CGRP antagonists and ditans pose competitive threats but also opportunities for partnerships and joint development.

---

FAQs

1. When did the patent for sumatriptan expire in key markets, and how did it impact sales?
The US patent for sumatriptan expired in 2007, leading to a surge in generic versions. Sales declined for branded formulations from their peak of USD 1.3 billion (2010) to approximately USD 1.2 billion in 2022, reflecting increased price competition but sustained demand [1].

2. How does the rise of CGRP inhibitors affect the sumatriptan market?
CGRP inhibitors primarily serve preventive roles but are increasingly used alongside acute treatments. Their targeted mechanism and improved safety profiles may reduce reliance on triptans over time, pressuring sumatriptan revenues [3].

3. Are there significant regulatory barriers impacting sumatriptan's market expansion?
Regulatory agencies require demonstration of safety and efficacy for new formulations and indications. Post-market safety monitoring for cardiovascular risks remains a focus, potentially delaying or complicating approval in certain regions [4].

4. What regional markets present the highest growth opportunities for sumatriptan or its formulations?
Emerging markets such as China, India, and Southeast Asia exhibit increasing migraine prevalence and expanding healthcare access, making them attractive for newer formulations and branded offerings [2].

5. What are the most promising lifecycle management strategies for sumatriptan?
Strategies include developing auto-injector devices, combination drugs, reformulations with faster onset, exploring biosimilar options, and expanding indications or administration routes in underserved regions.

---

References

[1] MarketResearch.com. "Global Migraine Market Analysis," 2022.
[2] World Health Organization. "Migraine prevalence and burden," 2020.
[3] Loder, E., et al. "Role of CGRP inhibitors in migraine management," The Journal of Headache and Pain, 2021.
[4] U.S. Food and Drug Administration. "Regulatory guidelines for migraine therapies," 2022.